Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Jul 1;109(7):2368-2371.
doi: 10.3324/haematol.2023.284436.

Phenomenon of tumor flare with talquetamab in a patient with extramedullary myeloma

Mark Forsberg  1 , Santiago Beltran  2 , Mendel Goldfinger  1 , Murali Janakiram  3 , Deepak Kalbi  4 , Amit Verma  1 , Dennis Cooper  1 , Nishi Shah  5
Affiliations
Case Reports

Phenomenon of tumor flare with talquetamab in a patient with extramedullary myeloma

Mark Forsberg et al. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Serial images of patient’s extramedullary fungating skin lesions.
Figure 2.
Figure 2.
Timeline comparing positron emission tomography scans from April 2023 and August 8, 2023. Scan show interval improvement in left proximal thigh mass and left subcutaneous nodularity, alongside treatment dates.
See this image and copyright information in PMC

References

    1. Howlader N, Noone AM, Krapcho M, et al. . SEER cancer statistics review (CSR) 1975-2018. Cronin KA eds. 2020.
    1. Kegyes D, Constantinescu C, Vrancken L. Patient selection for CAR T or BiTE therapy in multiple myeloma: which treatment for each patient? J Hematol Oncol. 2022;15(1):78. - PMC - PubMed
    1. Chari A, Minnema MC, Berdeja JG, et al. . Talquetamab, a T-cell– redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022;387(24):2232-2244. - PubMed
    1. Chanan-Khan A, Miller KC, Takeshita K, et al. . Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia CLL. Blood. 2005;106(10):3348-3352. - PubMed
    1. Wolchok JD, Hoos A, O’Day S, et al. . Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412-7420. - PubMed

Publication types

MeSH terms